...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith-Oncology Pipeline

fouremm - I totally agree with you! I feel there is a strong want for an IPO so that people can bail. I can't blame them but I feel we might end up with the same funding issues we now have with RVX. We have been able to get money at a much less dilutive value in ZCC but once the share price gets pushed down on the open market, I believe we would be in the same position as RVX. I would sooner wait for a buyout or at least some event that would support the share price on the open market when it gets there. Better management to take us through that would be very welcome also. We don't want to ignore the difference between what we are financing at and the OTC price. I know the OTC is different than a real exchange but it still shows what the market pressure can do before there is enough support for the price. Also note today's pressure there with it down to US$0.32. I think it needs more than a few Ph. 2 trials ongoing to support that price on the open market that we have been getting. So far, they have been able to convince some wealthy parties that there is a good story here and without an IPO, the company is the only place those can buy it in the volume they want so we are still able to get better value there. 

Share
New Message
Please login to post a reply